drugset / Trial / NCT00449930

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

NCT00449930

Phase 3 Completed 1050 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the efficacy and safety of sitagliptin in comparison to a commonly used medication in patients with type 2 diabetes

Timeline

Start
2007-03-01
Primary completion
2008-07-25
Completion
2008-07-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 500 mg
Subject Sitagliptin Small molecule 100 mg